Clinical trial NCT00990626: Seroquel XR in Schizophrenia Relapse Prevention
Official title: Seroquel XR in Schizophrenia Relapse Prevention
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia Relapse Prevention
Keywords: Seroquel XR
schizophrenia relapse prevention
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-10-07
Enrollment: 1600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Psychiatric outpatient clinics

Brief summary: The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients


Eligibility criteria: Inclusion Criteria:

* Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion Criteria:

* Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Primary outcomes:
measure: Rate of patients remained relapse free after 6 months of treatment
Secondary outcomes:
measure: Adherence rate of patients
measure: Quality of Life (QoL )
Other outcomes:
Locations:
city: Baja
country: Hungary
facility: Research Site
city: Barcs
country: Hungary
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Cegled
country: Hungary
facility: Research Site
city: Debrecen
country: Hungary
facility: Research Site
city: Dombovar
country: Hungary
facility: Research Site
city: Dunaujvaros
country: Hungary
facility: Research Site
city: Egerszalok
country: Hungary
facility: Research Site
city: Eger
country: Hungary
facility: Research Site
city: Emod
country: Hungary
facility: Research Site
city: Erd
country: Hungary
facility: Research Site
city: Esztergom
country: Hungary
facility: Research Site
city: Godollo
country: Hungary
facility: Research Site
city: Gyongyos
country: Hungary
facility: Research Site
city: Gyor
country: Hungary
facility: Research Site
city: Gyula
country: Hungary
facility: Research Site
city: Heves
country: Hungary
facility: Research Site
city: Hodmezovasarhely
country: Hungary
facility: Research Site
city: Janoshalma
country: Hungary
facility: Research Site
city: Jaszbereny
country: Hungary
facility: Research Site
city: Kalocsa
country: Hungary
facility: Research Site
city: Kecskemet
country: Hungary
facility: Research Site
city: Ketegyhaza
country: Hungary
facility: Research Site
city: Kiskunhalas
country: Hungary
facility: Research Site
city: Kistokaj
country: Hungary
facility: Research Site
city: Miskolc
country: Hungary
facility: Research Site
city: Nagyatad
country: Hungary
facility: Research Site
city: Nagykallo
country: Hungary
facility: Research Site
city: Nagykanizsa
country: Hungary
facility: Research Site
city: Nagykoros
country: Hungary
facility: Research Site
city: Oroshaza
country: Hungary
facility: Research Site
city: Pecs
country: Hungary
facility: Research Site
city: Pomaz
country: Hungary
facility: Research Site
city: Satoraljaujhely
country: Hungary
facility: Research Site
city: Soltvadkert
country: Hungary
facility: Research Site
city: Sopron
country: Hungary
facility: Research Site
city: Sumeg
country: Hungary
facility: Research Site
city: Szeged
country: Hungary
facility: Research Site
city: Szeghalom
country: Hungary
facility: Research Site
city: Szekesfehervar
country: Hungary
facility: Research Site
city: Szekszard
country: Hungary
facility: Research Site
city: Szentes
country: Hungary
facility: Research Site
city: Szigetszentmiklos
country: Hungary
facility: Research Site
city: Szigetvar
country: Hungary
facility: Research Site
city: Szolnok
country: Hungary
facility: Research Site
city: Szombathely
country: Hungary
facility: Research Site
city: Tatabanya
country: Hungary
facility: Research Site
city: Veszprem
country: Hungary
facility: Research Site
Study officials:
affiliation: National Psychiatric Centre
name: Attila Németh
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca Hungary MC
name: Lilla Szabó
role: STUDY_CHAIR
affiliation: AstraZeneca Hungary MC
name: Tamás Bábel
role: STUDY_DIRECTOR
References: